Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

Not Applicable

Completed

Conditions: Premature Birth of Newborn
Enterocolitis, Necrotizing

Interventions: Drug: Placebo
Drug: Ampicillin
Drug: Gentamicins

First Posted Date: 2015-06-22

Last Posted Date: 2020-10-08

Lead Sponsor: University of Chicago

Target Recruit Count: 27

Registration Number: NCT02477423

Locations: 🇺🇸
University of Chicago Medical Center - Comer Children's Hospital, Chicago, Illinois, United States

Milk Thistle in Trichotillomania in Children and Adults

Phase 2

Completed

Conditions: Hair Pulling Disorder
Trichotillomania

Interventions: Drug: Placebo
Drug: Milk Thistle

First Posted Date: 2015-06-17

Last Posted Date: 2020-11-20

Lead Sponsor: University of Chicago

Target Recruit Count: 22

Registration Number: NCT02473913

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Ultrasound-Guided Peripheral Venous Access Using AccuCath

Not Applicable

Completed

Conditions: Intravenous Access

Interventions: Device: AccuCath catheter
Device: Control

First Posted Date: 2015-06-11

Last Posted Date: 2020-12-30

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT02469038

Study the Impact of the CommunityRx Program on Health, Self-care and Cost

Not Applicable

Completed

Conditions: Health Behavior

Interventions: Other: HealtheRx

First Posted Date: 2015-05-06

Last Posted Date: 2022-05-11

Lead Sponsor: University of Chicago

Target Recruit Count: 411

Registration Number: NCT02435511

Locations: 🇺🇸
University of Chicago Medicine - Adult Emergency Department and Primary Care Group clinic, Chicago, Illinois, United States

Noninvasive Hemoglobin Monitor in the ER

Not Applicable

Withdrawn

Conditions: Hemoglobin

Interventions: Device: Radical-7 Noninvasive Hgb Monitor

First Posted Date: 2015-04-20

Last Posted Date: 2018-08-27

Lead Sponsor: University of Chicago

Registration Number: NCT02421250

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Phase 2

Terminated

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Biological: Obinutuzumab
Drug: Dexamethasone
Other: Quality-of-Life Assessment
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-04-17

Last Posted Date: 2018-06-06

Lead Sponsor: University of Chicago

Target Recruit Count: 2

Registration Number: NCT02420210

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Child Protective Outcomes Among Ultra-poor Families in Burkina Faso

Not Applicable

Completed

Conditions: Child Abuse
Child Maltreatment

Interventions: Behavioral: Trickle Up
Behavioral: Trickle Up Plus

First Posted Date: 2015-04-14

Last Posted Date: 2024-12-31

Lead Sponsor: University of Chicago

Target Recruit Count: 720

Registration Number: NCT02415933

Locations: 🇧🇫
Trickle Up Burkina Faso, Ouagadougou, Burkina Faso

Impact of the CommunityRx Program on Health, Service Utilization and Costs

Not Applicable

Completed

Conditions: Connecting Patients to Self-care Resources

Interventions: Behavioral: HealtheRx

First Posted Date: 2015-04-08

Last Posted Date: 2024-05-09

Lead Sponsor: University of Chicago

Target Recruit Count: 113295

Registration Number: NCT02411409

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Use Art-assist and Neupogen to Treat Chronic Limb Ischemia

Phase 4

Withdrawn

Conditions: Lower Limb Ischemia

Interventions: Drug: Neupogen
Device: Art-Assist Device

First Posted Date: 2015-04-06

Last Posted Date: 2016-04-08

Lead Sponsor: University of Chicago

Registration Number: NCT02408991

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

Phase 4

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: Fluticasone propionate
Drug: Fluticasone/Azelastine nasal spray
Drug: Placebo
Procedure: Nasal Allergen Challenge

First Posted Date: 2015-03-30

Last Posted Date: 2024-10-17

Lead Sponsor: University of Chicago

Target Recruit Count: 22

Registration Number: NCT02402465

Locations: 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy